You are here: Industry Insights > Spectrum

News List

Meridian Donates 900 Box Lunches to Spectrum Health Workers prnewswire
December 24, 2021
Meridian Health Plan of Michigan teamed up with Apple Spice Catering Company to provide 900 box lunches for Spectrum Health employees as a thank you for their dedicated efforts to care for the community during the COVID-19 pandemic.
Spectrum Pharmaceuticals Receives Complete Response Letter from FDA for Rolontis (eflapegrastim) drugs
August 10, 2021
Spectrum Pharmaceuticals today announced receipt of a Complete Response Letter (CRL) from the U.S. Food and Drug Administration (FDA) regarding the company’s Biologics License Application (BLA) for Rolontis® (eflapegrastim).
European molecular spectroscopy market to value $2.83bn by 2027 europeanpharmaceuticalreview
May 12, 2021
Research suggests the development of new instruments and growing government investments, particularly in Germany, will drive growth of the European molecular spectroscopy market.
Spectrum Therapeutics Partners with Emerald Clinics on Real World Evidence Research En-CPhI.CN
November 11, 2019
Spectrum Therapeutics, the medical division of Canopy Growth Corporation, is pleased to announce an Australian first for the company.
Spectrum Announces Asset Purchase and License for a Novel Immuno-Oncology Platform including Two Early Stage Assets firstwordpharma
May 10, 2019
The Focused Interferon Therapeutics (FIT) platform is a proprietary targeted antibody-interferon fusion technology with potential broad application in oncology
Eppendorf presents extended spectrum of applications for centrifugation biospectrumasia
March 19, 2019
The Rotor FA-6x250 extends the application range of the large benchtop Centrifuges 5910 R and 5920 R
Acrotech Biopharma to buy seven drugs from Spectrum for $300m pharmaceutical-technology
January 21, 2019
Aurobindo Pharma USA subsidiary Acrotech Biopharma has signed a definitive agreement to buy seven haematology and oncology drugs from Spectrum Pharmaceuticals for a consideration of up to $300m.....
Spectrum Submits BLA for ROLONTIS americanpharmaceuticalreview
December 29, 2018
Spectrum Pharmaceuticals announced the company submitted a Biologics License Application (BLA) with the U.S. Food and Drug Administration (FDA) for ROLONTIS (eflapegrastim).
Rare disease specialist Spectrum eyes potential $2B-plus sale: Bloomberg fiercepharma
June 29, 2018
Biopharma M&A has picked up this year with deals dominated by rare diseases and cancer, more than $34 billion all told, not counting Takeda's hefty $62 billion offer for Shire.